medigraphic.com
ISSN 1727-897X (Electronic)

2021, Number 6

<< Back Next >>

Medisur 2021; 19 (6)

Principles and medical applications of gene editing by CRISPR/Cas

Sánchez AR, Díaz AMT, Rodríguez DR, Miguel SPE

Language: Spanish
References: 38
Page: 1005-1014
PDF size: 212.46 Kb.


ABSTRACT

CRISPR/Cas technology is a simple, fast and extremely efficient method for gene editing. In order to describe the principles and medical application of this technology, a bibliographic review was carried out in Pubmed, SciELO, academic Google and the Cochrane Library, with the descriptors “gene editing”, “genome editing”, “CRISPR-Cas systems”, and “CRISPR-associated protein 9”. The CRISPR/Cas9 system comprises a Cas endonuclease and two types of RNA. Cas cuts the invading phage DNA into segments, which are integrated into the CRISPR sequence as spacers. Subsequently, the CRISPR sequence is transcribed to generate crRNA and tracrRNA, which form a double-stranded RNA structure that recruits Cas for cleavage. The introduction of the system into the cell interior occurs with plasmids, RNA or ribonucleoproteins. A nuclear localization sequence allows CRISPR / Cas9 to enter the nucleus. CRISPR/Cas9 technology is an efficient tool for precise gene editing with great impact on scientific research.


REFERENCES

  1. Riveros R, Méndez A, Benítez N, Nara E, Fernández D. Sistema CRISPR/Cas: Edición genómica de precisión. Mem Inst Investig Cienc Salud[Internet]. 2020[citado 10/08/2021];18(1):[aprox. 20p]. Disponible en: http://archivo.bc.una.py/index.php/RIIC/article/view/1670/1677

  2. Mei Y, Wang Y, Chen H, Sun ZS, Ju XD. Recent Progress in CRISPR/Cas9 Technology. J Genet Genomics. 2016;43:63e75.

  3. Fajrial AK, He QQ, Wirusanti NI, Slansky JE, Ding X. A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing. Theranostics. 2020;10(12):5532-49.

  4. Razzaq A, Saleem F, Kanwal M, Mustafa G, Yousaf S, Imran HM, et al. Modern Trends in Plant Genome Editing: An Inclusive Review of the CRISPR/Cas9 Toolbox. Int J Mol Sci. 2019;20(16):4045.

  5. Wu X, Ma W, Mei C, Chen X, Yao Y, Liu Y, et al. Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment. J Exp Clin Cancer Res. 2020;39:97.

  6. Chekani S, Gharib Mombeni E, Birhan M, and Yousefi M. CRISPR/Cas9 gene editing technology and its application to the coronavirus disease (COVID-19), a review. J Life Sci Biomed. 2020;10(1):1-9.

  7. Bashir M, Ali Q, Rashid M, Malika A. CSRISPR-Cas9 in genome editing: A nature gifted molecular tool. Biol Clin Sci Res J. 2020;2020(1):e018.

  8. Thurtle DM, Te L. Molecular biology at the cutting edge: A review on CRISPR/CAS9 gene editing for undergraduates. Biochem Mol Biol Edu. 2018;46(2):195-205.

  9. Canet D. CRISPR-Cas9: Técnicas y aplicaciones [Tesis]. Cataluña, España: Universitat Oberta de Catalunya; 2017[citado 4/08/2021]. Disponible en: Disponible en: http://hdl.handle.net/10609/63825

  10. Jaganathan D, Ramasamy K, Sellamuthu G, Jayabalan S, Venkataraman G. CRISPR for Crop Improvement: An Update Review. Front Plant Sci. 2018;9:985.

  11. Syding LA, Nickl P, Kasparek P, Sedlacek R. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review. Cells. 2020;9(4):993.

  12. Thaldar D, Botes M, Shozi B, Townsend B, Kinderlerer J. Human germline editing: Legal-ethical guidelines for South Africa. S Afr J Sci. 2020;116(9-10):1-7.

  13. Munawar N, Ahmad A. CRISPR/Cas System: An Introduction. CRISPR Crops. 2021;9:1-35.

  14. Khan S, Mahmood MS, Rahman S, Zafar H, Habibullah S, Khan Z, et al. CRISPR/Cas9: the Jedi against the dark empire of diseases. J Biomed Sci. 2018;25:29.

  15. Lone BA, Karna SK, Ahmad F, Shahi N, Pokharel YR. CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering. Genet Res Int. 2018;2018:3797214.

  16. Givens BE, Naguib YW, Geary SM, Devor EJ, Salem AK. Nanoparticle based delivery of CRISPR/Cas9 genome editing therapeutics. AAPS J. 2018;20(6):108.

  17. Ahmad HI, Ahmad MJ, Asif AR, Adnan M, Iqbal MK, Mehmood K, et al. A Review of CRISPR-Based Genome Editing: Survival, Evolution and Challenges. Curr Issues Mol Biol. 2018;28(1):47-68.

  18. Song R, Zhai Q, Sun L, Huang E, Zhang Y, Zhu Y, et al. CRISPR/Cas9 genome editing technology in filamentous fungi: progress and perspective. Appl Microbiol Biotechnol. 2019;103(17):6919-32.

  19. Han HA, Sheng JK, Soh BS. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. J Mol Med (Berl). 2020;98(5):615-32.

  20. Li Y, Glass Z, Huang M, Chen ZY, Xu Q. Ex Vivo Cell-Based CRISPR/Cas9 Genome Editing for Therapeutic Applications. Biomaterials. Biomaterials. 2020;234:119711.

  21. Okoli A, Okeke MI, Tryland M, Moens U. CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development. Viruses. 2018;10(1):50.

  22. Rodríguez DR, Ramírez R, Garza MA, Garza AL, Barrera HA. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review). Int J Mol Med. 2019;43(4):1559-74.

  23. Xu T, Li L, Liu YC, Cao W, Chen J, Hu S, et al. CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity. Int J Biol Sci. 2020;16(13):2283-95.

  24. Cribbs AP, Perera SM. Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction. Yale J Biol Med. 2017;90(4):625-34.

  25. Jacinto FV, Link W, Ferreira BI. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine. J Cell Mol Med. 2020;24(7):3766-78.

  26. Gao Q, Dong X, Xu Q, Zhu L, Wang F, Hou Y, et al. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy. Cancer Med. 2019;8:4254-64.

  27. Kaushik I, Ramachandran S, Srivastava SK. CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment. Semin Cell Dev Biol. 2019;96:4-12:31054324.

  28. Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Delivery. 2018;25(1):1234-57.

  29. Mohammed ZS, Rajh W, Al-Kraity H. Contemporary Evolution in CRISPR-CAS9 System Technology and their Uses in Treatment of Human Common Diseases: A Review. Medico-legal Update. 2021;21(2):1344-51.

  30. Maganti HB, Bailey AJ, Kirkham AM, Shorr R, Pineault N, Allan DS. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies. STEM CELLS Transl Med. 2021;1-12.

  31. Xiao Q, Guo D, Chen S. Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy. Front Cell Infect Microbiol. 2019;9:69.

  32. Lee C. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules. 2019;24(7):1349.

  33. Bellizzi A, Ahye N, Jalagadugula G, Wollebo HS. A broad application of CRISPR Cas9 in infectious diseases of central nervous system. J Neuroimmune Pharmacol. 2019;14(4):578-94.

  34. Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz K. The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine. 2018;1(1):e1003.

  35. Motta BM, Pramstaller PP, Hicks AA, Rossini A. The Impact of CRISPR/Cas9 Technology on Cardiac Research: From Disease Modelling to Therapeutic Approaches. Stem Cells International. 2017;2017:8960236.

  36. Lima NS. CRISPR/Cas9: reflexiones bioéticas sobre las modificaciones genómicas. BAG, J Basic Appl Genet[Internet]. 2018[citado 23/05/2021];29(1):[aprox. 9p]. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1852-62332018000100001&lng=es

  37. Thaldar D, Botes M, Shozi B, Townsend B, Kinderlerer J. Human germline editing: Legal-ethical guidelines for South Africa. S Afr J Sci. 2020;116(9-10):1-7.

  38. Félix Dantas CH, Valença Ferraz C, Rocha de Morales Falcão J. La protección de la diversidad en el patrimonio genético: implicaciones bioéticas y jurídicas en el uso de CRISPR-Cas9 como herramienta de edición genómica en humanos. Rev Bioética y Derecho[Internet]. 2020[citado 23/05/2021];(49):[aprox. 11p]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1886-58872020000200006&lng=es




2020     |     www.medigraphic.com